NCT01382238 - Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Infections, Human Immunodeficiency Virus and Herpesviridae

Interventions

DRUG

Dolutegravir 50 mg tablet

Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.

DRUG

Dolutegravir 50 mg oral granules

Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.

Trial Locations (1)

GSK Investigational Site, Austin